Study of fluorouracil, epirubicin and cyclophosphamide followed by docetaxel as preoperative chemotherapy in primary breast cancer (JBCRG-02)

Study of fluorouracil, epirubicin and cyclophosphamide followed by docetaxel as preoperative chemotherapy in primary breast cancer (JBCRG-02) - JBCRG-02 (Study of FEC-DOC100 as primary systemic chemotherapy for operable breast cancer)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000020

Enrollment

Registered

2005-07-05

Start date

2004-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary breast cancer

Interventions

Fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, q3w x 4 cycles, followed by Docetaxel 100 mg/m2, q3w x 4 cycles as Primary systemic Chemotherapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Histologically-proven breast cancer T1c-3N0M0/T1-3N1M0 No prior therapy for breast cancer Performance status 0-1 Adequate hematologic, renal, hepatic and cardica function Written informed consent

Exclusion criteria

Exclusion criteria: Hypersensitivity for drug Serious coexisting illness Active double cancer Bilateral breast cancer Male breast cancer Pregnant or postpartum women

Design outcomes

Primary

Measure	Time frame
Safety, clinical and histologic effect	—

Secondary

Measure	Time frame
Breast-conserving rate, disease-free survival	—

Countries

Japan

Contacts

Public ContactKatsumasa Kuroi

JBCRG Head Office

office@jbcrg.jp03-6264-8873

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026